Voriconazole-Induced Hepatotoxicity in a Patient with Pulmonary Aspergillosis: A Case Report

References

• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326
   PubMed Web of Science ®Google Scholar
• Wang J-L, Chang C-H, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010;54(6):2409–2419. doi:10.1128/AAC.01657-09
   PubMed Web of Science ®Google Scholar
• Hamada Y, Ueda T, Miyazaki Y, et al. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: a multicentre study conducted in Japan. Mycoses. 2020;63(8):779–786. doi:10.1111/myc.13129
   PubMed Web of Science ®Google Scholar
• Wang T, Miao L, Shao H, et al. Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: a nationwide multi-centre retrospective study. Int J Antimicrob Agents. 2022;60(5–6):106692. doi:10.1016/j.ijantimicag.2022.106692
   PubMed Web of Science ®Google Scholar
• Jin H, Wang T, Falcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772–1785. doi:10.1093/jac/dkw045
   PubMed Web of Science ®Google Scholar
• Wang T, Zhu H, Sun J, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014;44(5):436–442. doi:10.1016/j.ijantimicag.2014.07.013
   PubMed Web of Science ®Google Scholar
• Lin X-B, Z-W L, Yan M, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients. Br J Clin Pharmacol. 2018;84(7):1587–1597. doi:10.1111/bcp.13595
   PubMed Web of Science ®Google Scholar
• Lee S, Kim B-H, Nam W-S, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2012;52(2):195–203. doi:10.1177/0091270010395510
   PubMed Web of Science ®Google Scholar
• Scholz I, Oberwittler H, Riedel K-D, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906–915. doi:10.1111/j.1365-2125.2009.03534.x
   PubMed Web of Science ®Google Scholar
• Maertens JA, Rahav G, Lee D-G, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a Phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499–509. doi:10.1016/S0140-6736(21)00219-1
   PubMed Web of Science ®Google Scholar
• Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42(12):1726–1734. doi:10.1086/504328
   PubMed Web of Science ®Google Scholar
• Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34(2):134–144. doi:10.1055/s-0034-1375955
   PubMed Web of Science ®Google Scholar
• Latgé J-P, Chamilos G. Aspergillus fumigatus and Aspergillosis in 2019. Clin Microbiol Rev. 2019;33(1). doi:10.1128/CMR.00140-18
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis. 2008;46(3):327–360. doi:10.1086/525258
   PubMed Web of Science ®Google Scholar
• Shen K, Gu Y, Wang Y, et al. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases. Ther Adv Drug Saf. 2022;13:20420986221127503. doi:10.1177/20420986221127503
   Web of Science ®Google Scholar
• Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011;55(10):4782–4788. doi:10.1128/AAC.01083-10
   PubMed Web of Science ®Google Scholar
• Tverdek FP, Kofteridis D, Kontoyiannis DP. Antifungal agents and liver toxicity: a complex interaction. Expert Rev Anti Infect Ther. 2016;14(8):765–776. doi:10.1080/14787210.2016.1199272
   PubMed Web of Science ®Google Scholar
• Tang D, Yan M, Song B-L, et al. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: a prospective observational study. Br J Clin Pharmacol. 2021;87(4):1890–1902. doi:10.1111/bcp.14578
   PubMed Web of Science ®Google Scholar
• Luong M-L, Al-Dabbagh M, Groll AH, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016;71(7):1786–1799. doi:10.1093/jac/dkw099
   PubMed Web of Science ®Google Scholar
• Ueda K, Nannya Y, Kumano K, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol. 2009;89(5):592–599. doi:10.1007/s12185-009-0296-3
   PubMed Web of Science ®Google Scholar
• Zonios D, Yamazaki H, Murayama N, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 2014;209(12):1941–1948. doi:10.1093/infdis/jiu017
   PubMed Web of Science ®Google Scholar
• Chu HY, Jain R, Xie H, Pottinger P, Fredricks DN. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis. 2013;13:105. doi:10.1186/1471-2334-13-105
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649–663. doi:10.2165/00003088-200645070-00002
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hou K, Liu F, et al. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: systematic review and meta-analysis. Mycoses. 2021;64(8):860–873. doi:10.1111/myc.13293
   PubMed Web of Science ®Google Scholar
• Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 2017;102(1):45–51. doi:10.1002/cpt.583
   PubMed Web of Science ®Google Scholar
• S-L W, Cheng C-N, Wang -C-C, Lin S-W, Kuo C-H. Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress. Toxicol Appl Pharmacol. 2020;403:115157. doi:10.1016/j.taap.2020.115157
   PubMed Web of Science ®Google Scholar
• S-L W, Wei T-Y, Lin S-W, K-Y S, Kuo C-H. Metabolomics investigation of voriconazole-induced hepatotoxicity in mice. Chem Res Toxicol. 2019;32(9):1840–1849. doi:10.1021/acs.chemrestox.9b00176
   PubMed Web of Science ®Google Scholar
• Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges. Int J Mol Sci. 2021;22(6). doi:10.3390/ijms22062954
   Web of Science ®Google Scholar
• Foo H, Gottlieb T. Lack of cross-hepatotoxicity between voriconazole and posaconazole. Clin Infect Dis. 2007;45(6):803–805. doi:10.1086/521174
   PubMed Web of Science ®Google Scholar
• Martínez-Casanova J, Carballo N, Luque S, Sorli L, Grau S. Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis. Infect Drug Resist. 2018;11:317–321. doi:10.2147/IDR.S154457
   PubMed Web of Science ®Google Scholar
• Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses. 2013;56(3):304–310. doi:10.1111/myc.12023
   PubMed Web of Science ®Google Scholar